scholarly journals Application of Mesenchymal and Renal Stem Cells in Kidney Diseases Tratment- A Exploration Technology

2020 ◽  
Vol 10 (2) ◽  
pp. 5415-5423
Author(s):  
D. O. BEZERRA ◽  
◽  
E. R. D. F. S. SILVA ◽  
M. L. GOIS ◽  
Y. K. P. CARVALHO ◽  
...  
Keyword(s):  
Stem Cells ◽  
Kidney Diseases ◽  
Renal Stem Cells

scholarly journals Regenerative Medicine for the Kidney: Renotropic Factors, Renal Stem/Progenitor Cells, and Stem Cell Therapy

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Akito Maeshima ◽  
Masao Nakasatomi ◽  
Yoshihisa Nojima
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Regenerative Medicine ◽  
Progenitor Cells ◽  
Kidney Diseases ◽  
Embryonic Stem ◽  
Stem Cell Markers ◽  
Hematopoietic Stem ◽  
Cell Therapies ◽  
Renal Stem Cells

The kidney has the capacity for regeneration and repair after a variety of insults. Over the past few decades, factors that promote repair of the injured kidney have been extensively investigated. By using kidney injury animal models, the role of intrinsic and extrinsic growth factors, transcription factors, and extracellular matrix in this process has been examined. The identification of renal stem cells in the adult kidney as well as in the embryonic kidney is an active area of research. Cell populations expressing putative stem cell markers or possessing stem cell properties have been found in the tubules, interstitium, and glomeruli of the normal kidney. Cell therapies with bone marrow-derived hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, and amniotic fluid-derived stem cells have been highly effective for the treatment of acute or chronic renal failure in animals. Embryonic stem cells and induced pluripotent stem cells are also utilized for the construction of artificial kidneys or renal components. In this review, we highlight the advances in regenerative medicine for the kidney from the perspective of renotropic factors, renal stem/progenitor cells, and stem cell therapies and discuss the issues to be solved to realize regenerative therapy for kidney diseases in humans.

Regrow or Repair: An Update on Potential Regenerative Therapies for the Kidney

2021 ◽  
pp. ASN.2021081073
Author(s):  
Melissa Little ◽  
Benjamin Humphreys
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Kidney Development ◽  
Transcriptional Analysis ◽  
Cell Recruitment ◽  
Renal Stem Cells ◽  
Induced Pluripotent ◽  
Stem Cell Populations ◽  
A Site ◽  
Regenerative Therapies

Fifteen years ago, this journal published a review outlining future options for regenerating the kidney. At that time, stem cell populations were being identified in multiple tissues, the concept of stem cell recruitment to a site of injury was of great interest, and the possibility of postnatal renal stem cells was growing in momentum. Since that time, we have seen the advent of human induced pluripotent stem cells, substantial advances in our capacity to both sequence and edit the genome, global and spatial transcriptional analysis down to the single-cell level, and a pandemic that has challenged our delivery of health care to all. This article will look back over this period of time to see how our view of kidney development, disease, repair, and regeneration has changed and envision a future for kidney regeneration and repair over the next 15 years.

scholarly journals Stem cell-based treatment of kidney diseases

2020 ◽  
Vol 245 (10) ◽  
pp. 902-910
Author(s):  
Binbin Pan ◽  
Guoping Fan
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cells ◽  
Acute Kidney Injury ◽  
Stem Cell ◽  
Kidney Disease ◽  
Cell Therapy ◽  
Kidney Diseases ◽  
Kidney Injury ◽  
Great Promise ◽  
Kidney Organoids

Kidney dysfunction, including chronic kidney disease and acute kidney injury, is a globally prevalent health problem. However, treatment regimens are still lacking, especially for conditions involving kidney fibrosis. Stem cells hold great promise in the treatment of chronic kidney disease and acute kidney injury, but success has been hampered by insufficient incorporation of the stem cells in the injured kidney. Thus, new approaches for the restoration of kidney function after acute or chronic injury have been explored. Recently, kidney organoids have emerged as a useful tool in the treatment of kidney diseases. In this review, we discuss the mechanisms and approaches of cell therapy in acute kidney injury and chronic kidney disease, including diabetic kidney disease and lupus nephritis. We also summarize the potential applications of kidney organoids in the treatment of kidney diseases. Impact statement Stem cells hold great promise in regenerative medicine. Pluripotent stem cells have been differentiated into kidney organoids to understand human kidney development and to dissect renal disease mechanisms. Meanwhile, recent studies have explored the treatment of kidney diseases using a variety of cells, including mesenchymal stem cells and renal derivatives. This mini-review discusses the diverse mechanisms underlying current renal disease treatment via stem cell therapy. We postulate that clinical applications of stem cell therapy for kidney diseases can be readily achieved in the near future.

scholarly journals Bone Marrow Mesenchymal Stem Cells Ameliorate Cisplatin-Induced Renal Fibrosis via miR-146a-5p/Tfdp2 Axis in Renal Tubular Epithelial Cells

2021 ◽  
Vol 11 ◽  
Author(s):  
Lei Wu ◽  
Chao Rong ◽  
Qing Zhou ◽  
Xin Zhao ◽  
Xue-Mei Zhuansun ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Epithelial Cells ◽  
Renal Fibrosis ◽  
Kidney Diseases ◽  
Tubular Epithelial Cells ◽  
Renal Tubular Epithelial Cells ◽  
Marrow Mesenchymal Stem Cells ◽  
Renal Tubular

Mesenchymal stem cells (MSCs) have regenerative properties in acute kidney injury (AKI). However, the potential function of MSCs in chronic kidney disease remains elusive. Renal fibrosis is the common endpoint of chronic progressive kidney diseases and causes a considerable health burden worldwide. In this study, the protective effects of bone marrow mesenchymal stem cells (BM-MSCs) were assessed in repeated administration of low-dose cisplatin-induced renal fibrosis mouse model in vivo as well as a TGF-β1-induced fibrotic model in vitro. Differentially expressed miRNAs in mouse renal tubular epithelial cells (mRTECs) regulated by BM-MSCs were screened by high-throughput sequencing. We found microRNA (miR)-146a-5p was the most significant up-regulated miRNA in mRTECs. In addition, the gene Tfdp2 was identified as one target gene of miR-146a-5p by bioinformatics analysis. The expression of Tfdp2 in the treatment of BM-MSCs on cisplatin-induced renal injury was evaluated by immunohistochemistry analysis. Our results indicate that BM-MSC attenuates cisplatin-induced renal fibrosis by regulating the miR-146a-5p/Tfdp2 axis in mRTECs.

scholarly journals A comprehensive review on application of stem cells for kidney diseases

2020 ◽  
Vol 11 (2) ◽  
pp. 1377-1385
Author(s):  
Chetan Kumar V H ◽  
Famna Roohi N K ◽  
Gowda D V
Keyword(s):  
Stem Cells ◽  
Bacterial Infections ◽  
Complex Disease ◽  
Ethical Issues ◽  
Kidney Diseases ◽  
Embryonic Stem ◽  
Turnaround Time ◽  
Embryoid Bodies ◽  
Renal Progenitor Cells ◽  
The Impact

The recognition of kidney failure as a complex disease requires multifactorial therapy in order to correct the conventional nonfactorial deficiency. Firstly, self-renewal means the ability of most organisms to reproduce without separation or aging; secondly, more than one form of a mature somatic cell is identified by each of the three regardless of kidney disorders, it can lead to loss of the environment, often bacterial infections. The reconstruction of the kidney has produced a spectacular response in this framework. The restoration of weakened and new kidneys is an alternative to renal replacement therapy. Both teratomas and embryoid bodies consist of three different layers of embryonic germs. Induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are present. These either provide useful therapeutical resources or can explore pathophysiology, including kidney diseases or infection. The benefit of ESCs is that they are relatively quick to receive and no longer subject to licensing/realty fees. Nevertheless, there are still some major concerns, such as ethical issues, the high risks to degeneration of neoplasm and immunocompatibility. The great benefit of iPSCs is that they have the same genetic history they drive making them an excellent method for studying the impact of genetic variants on disease path the key risk associated with the use of iPSCs are oogenesis, Tumorigenicity, and immunogenicity, the presence of an epigenetic memory, technical and economic issue associatedwith their long turnaround time and the presence of loyalties are the key risks associated with the use of iPSCs. Human pluripotent SCs have two major areas of use in kidney regeneration: they can be used by way organoid, scaffold,organ-on-a-chip, or blastocyst experiment to develop a "new kidney" or part of it. Renal progenitor cells are an alternative to either test or modulate regeneration of the kidney, offering significant benefits in the field. For encouraging us to hypothesize their medical use, a deeper understanding of the biology of pluripotent SCs is necessary.

Kidney stem cells

2015 ◽  
Author(s):  
Oren Pleniceanu ◽  
Benjamin Dekel
Keyword(s):  
Stem Cells ◽  
Progenitor Cells ◽  
Human Stem Cells ◽  
Haematopoietic Stem Cells ◽  
End Stage Renal Failure ◽  
Renal Stem Cells ◽  
Nephron Progenitors ◽  
End Stage ◽  
Kidney Stem Cells ◽  
Potential Use

End-stage renal failure is a major cause of death with currently only dialysis and transplantation available as therapeutic options, each with its own limitations and drawbacks. To allow regenerative medicine-based kidney replacement therapies and due to the fact that neither haematopoietic stem cells nor mesenchymal stem cells, the most accessible human stem cells, can be used to derive genuine nephron progenitors, much attention has been given to finding adult renal stem cells. Several candidates for this have been described, but their true identity as stem or progenitor cells and their potential use in therapy has not yet been shown. However, the analysis of embryonic renal stem cells, specifically stem/progenitor cells that are induced into the nephrogenic pathway to form nephrons until the 34th week of gestation, has been much more conclusive.

Sign in / Sign up

Export Citation Format

Share Document